Lack of clopidogrel-statin interaction in patients undergoing coronary stent implantation;Ausencia de interacción clopidogrel-estatina en pacientes sometidos a implante de "stent" coronario

Arquivos Brasileiros de Cardiologia

Volumn 95, Issue 3, 2010, Pages 321-327

  Serrano Jr , Carlos Vicente ^a   Soeiro, Alexandre De Matos ^a   Araújo, Leila Fernandes ^a   Jabot, Bruna ^a   Rached, Fabiana ^a   Orii, Noemia Mie ^a   Nicolau, José Carlos ^a   Duarte, Alberto J ^a   Ramires, José Antonio F ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Angioplasty transluminal percutaneous coronary; Hidroxymethylglutaryl CoA reductase inhibitors; Simvastatin; Stents utilization

Indexed keywords

ATORVASTATIN; CLOPIDOGREL; FIBRINOGEN RECEPTOR; PADGEM PROTEIN; SIMVASTATIN;

ADULT; AGED; ANGIOPLASTY; ARTICLE; CARDIAC PATIENT; CONTROLLED STUDY; CORONARY STENT; DRUG ACTIVITY; DRUG EFFECT; DRUG SCREENING; DRUG USE; FEMALE; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; STABLE ANGINA PECTORIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT;

EID: 78049323518     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2010005000106     Document Type: Article

References (29)

1. CAPRIE Steering Committee. A randomized, blinded, trial of clopidrogrel versus aspirin in patients at risk for ischemic events (CAPRIE). Lancet. 1996; 348 (9038): 1329-39.
2. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH, Classics Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation. 2000; 102 (6): 624-9. (Pubitemid 30640661)
3. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, Clopidogrel in Unstable Angina Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-elevation .N Engl J Med. 2001; 345 (7): 494-502.
4. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation. 2003; 107 (1): 32-7. (Pubitemid 36070929)
5. Neubauer H, Gunesdogan B, Hanefeld C, Spiecker M, Mügge A. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function - a flow cytometry study. Eur Heart J. 2003; 24 (19): 1744-9.
6. Hochholzer W, Trenk D, Frundi D, Blanke P, Fischer B, Andris K, et al. No impact of statins metabolized by CYP3A4 on the antiplatelet effect and the clinical outcome after a 600 mg loading dose of clopidogrel in patients undergoing elective coronary angiography [abstract]. Eur Heart J. 2005; 26 (Suppl): 483.
7. Serebruany VL, Midei MG, Malinin AI, Oshrine BR, Lowry DR, Sane DC, et al. Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. Arch Intern Med. 2004; 164 (18): 2051-7.
8. Savi P, Herbert JM, Pflieger AM, Dol F, Delebassee D, Combalbert J, et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol. 1992; 44 (3): 527-32.
9. Savi P, Combalbert J, Gaich C, Rouchom MC, Maffrand JP, Berger Y, et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost. 1994; 72 (2): 313-7.
10. Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000; 84 (5): 891-6.
11. Geiger J, Brich J, Honig-Liedl P, Eigenthaler M, Schanzenbächer P, Herbert JM, et al. Specific impairment of human platelet P2Y(ac) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol. 1999; 19 (8): 2007-11. (Pubitemid 29379936)
12. Nicolau JC, Costa OC. Terapêutica antiplaquetária com ênfase nos bloqueadores no complexo glicoprotéico IIb/IIIa. In: Nicolau JC, Neto JAM. Síndromes isquêmicas miocárdicas instáveis. São Paulo: Editora Atheneu; 2001. p. 277-92.
13. Tcheng JE, Campbell ME. Platelet inhibition strategies in percutaneous coronary intervention: competition or coopetition? J Am Coll Cardiol. 2003; 42 (7): 1196-8.
14. Osamah H, Mira R, Sorina S, Shlomo K, Michael A. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets. Br J Clin Pharmacol.1997; 44 (1): 77-83.
15. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA. 1998; 279 (20): 1643-50.
16. Rang HP, Dale MM, Ritter JM. Aterosclerose e metabolismo de lipoproteínas. In: Rang HP, Dale MM, Ritter JM. Farmacologia. 4a ed. Rio de Janeiro: Editora Guanabara Koogan; 2001. p. 247-54.
17. Muller I, Besta F, Schulz C, Li Z, Massberg S, Gawaz M. Effects of statins on platelet inhibition by a high loading dose of clopidogrel. Circulation. 2003; 108 (18): 2195-7.
18. Trenk D, Hochholzer W, Frundi D, Stratz C, Valina CM, Bestehorn HP, et al. Impact cytocrome P450 3A4-metabolized statins on the antiplatelet effect of a 600 mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement. Thromb Haemost. 2008; 99 (1): 174-81.
19. Liao JK. Effects of statins on 3-hydroxy-3- methylglutaryl coenzyme-A reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol. 2005; 96 (5A): 24F-33F.
20. Serrano CV Jr, Yoshida VM, Venturinelli ML, D'Amico E, Monterio HP, Ramires JA, et al. Effect of simvastatin on monocyte adhesion molecule expression in patients with hypercholesterolemia. Atherosclerosis. 2001; 157 (2): 505-12. (Pubitemid 32717258)
21. Serrano CV Jr, Ascer E, Nicolau JC, Ramires JAF. The effect of atorvastatin on proinflammatory mediators and endothelial adhesion molecule expression. Eur Heart J. 2001; 22: 646.
22. Jneid H, Bhatt DL, Corti R, Badimon JJ, Fuster V, Francis GS. Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study. Arch Intern Med. 2003; 163 (10): 1145-53.
23. Lotfi A, Schweiger MJ, Giugliano GR, Murphy SA, Cannon CP. High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients. A Pravastatin or Atorvastatin Evaluation and Infection Therapy - Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis. Am Heart J. 2008; 155 (5): 954-8.
24. Saw J, Brennan DM, Steinhubl SR, Bhatt DL, Mak KH, Fox K, et al. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA Trial. J Am Coll Cardiol. 2007; 50 (4): 291-5.
25. Mehta SR, Yusuf S. Clopidogrel in unstable angina to prevent Recurrent Events (CURE) Study Investigators. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J. 2000; 21 (24): 2033-41.
26. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2002; 40 (7): 1366-74.
27. Mehta SR, Yusuf S, Peters RJG, Bertrand ME, Lewis BC, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001; 358 (9281): 527-33.
28. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention. J Am Coll Cardiol. 2007; 49 (12): 1272-8.
29. Shaw SM, Fildes JE, Yonan N, Williams SG. Pleiotropic effects and cholesterol-lowering therapy. Cardiology. 2009; 112 (1): 4-12.